Lorlatinib时代的ALK抑制剂耐药性导航：NSCLC的综合视角。

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2024-04-17 DOI:10.1080/14737140.2024.2344648

Maria Gemelli, Adriana Albini, Gianpiero Catalano, Matteo Incarbone, Maria Cannone, Emanuela Balladore, Riccardo Ricotta, Giuseppe Pelosi

引用次数: 0

摘要

非小细胞肺癌（NSCLC）中出现的无性淋巴瘤激酶（ALK）重排使靶向治疗发生了革命性的变化。在这一充满活力的格局中，新型 ALK 抑制剂和新的靶向药物的出现为靶向治疗带来了新的机遇。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Navigating resistance to ALK inhibitors in the Lorlatinib Era: a comprehensive perspective on NSCLC.

The emergence of anaplastic lymphoma kinase (ALK) rearrangements in non-small cell lung cancer (NSCLC) has revolutionized targeted therapy. This dynamic landscape, featuring novel ALK inhibitors an...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.